

## Rare Association of Macroprolactinemia and Empty Sella Syndrome

Ach MT\*, Kacem NM, Abed EYH, Beizig AM, Chadli CM and Ach K

Endocrinology and Diabetes Department, University Hospital Farhat Hached, Sousse, Tunisia

\*Corresponding author: Ach MT, Endocrinology and Diabetes Department, University Hospital Farhat Hached, Sousse, Tunisia, Tel: +33 6 41 23 51 48; E-mail: ach.taieb@gmail.com

Received date: November 15, 2016; Accepted date: December 05, 2016; Published date: December 14, 2016

Copyright: © 2017 Ach MT, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

### Abstract

**Background:** Macroprolactinemia is a polymeric form of prolactin-release, causing mildly symptomatic clinical pictures. The former can be isolated or associated with other causes of hyperprolactinemia. The association with an empty sella syndrome is rare. We report a case of a female patient discovered with this association.

**Observation:** It's about a female patient 47 years old, followed up since the age of 31 years for bilateral galactorrhea and a spaniomenorrhea. There has been no associated drug intake. Her exploration has showed a serum prolactin level of 635 mIU/L. Thyroid test results were normal T4=10.2 ng/L and TSH=1.76 mIU/L. A brain scan has showed an empty sella turcica. Despite the unchanged levels of prolactinemia, the evolution under dopaminergic 5 mg/D has been marked by the occurrence of a pregnancy with persistent moderate hyperprolactinemia in the postpartum. Chromatography has showed a predominance of the macroprolactin form with: Prolactin monomer at 4.8%, Big Prolactin at 5% and Big Big Prolactin at 83%, thus stopping bromocriptine.

**Conclusion:** Our observation suggests that macroprolactinemia can be associated with conventional etiologies of moderate hyperprolactinemia as the empty sella syndrome. Its detection would prevent the use of dopaminergic therapy which seems not useful.

**Keywords:** Hyperprolactinemia; Macroprolactinemia; Empty sella syndrome; Pregnancy

**Abbreviations:** PRL: Prolactin; FSH: Follicle stimulating hormone; LH: Luteinizing hormone

### Introduction

Prolactin (PRL) exists in the blood under many forms: monomeric (60-85%), polymeric and PRL-protein complexes of higher molecular weight [1].

Macroprolactinemia is a polymeric form of prolactin-release, causing mildly symptomatic clinical pictures [2]. The former can be isolated or associated with other causes of hyperprolactinemia [3].

We report the case of a macroprolactinemia being discovered in a patient with an empty sella Syndrome. We report the case of a macroprolactinemia being discovered in a patient with an empty sella Syndrome.

### Observation

It consists in a 47 years old female patient, who has been followed up since the age of 31 years for bilateral galactorrhea and a spaniomenorrhea. There has been no associated drug intake. Her exploration has showed a serum prolactin level of 635 mIU/L. Thyroid test results were normal T4=10.2 ng/L and TSH=1.76 mIU/L. A brain scan has showed an empty sella turcica. Despite the unchanged levels of prolactinemia, the evolution under dopaminergic 5 mg/D has been marked by the occurrence of a pregnancy with persistent moderate hyperprolactinemia in the postpartum.

The patient has had menopause at the age of 47, with elevated gonadotrophins FSH=78 mIU/mL, LH=33 mIU/mL and estradiol: 35 pg/mL. Chromatography has showed a predominance of the macroprolactin form with: Prolactin monomer at 4.8%, Big Prolactin at 5% and Big Big Prolactin at 83%, thus stopping bromocriptine.

### Discussion

We report a case of a patient with an association of empty sella Syndrome and macroprolactinemia.

The clinical picture may be completely asymptomatic [2] or mildly symptomatic in 22-46% of cases as in our observation [3].

Furthermore, the macroprolactinemia has been raised in our perception ahead of the non-functional character of hyperprolactinemia evidenced by the occurrence of pregnancy and after the menopause, although hyperprolactinemia has persisted which seems insensitive to bromocriptine [4], suggesting its non-functional character. Andersen et al. have as well evoked a case of a female patient, in whom a pregnancy occurred [5], with macroprolactinemia. The frequency of macroprolactinemia in pregnancy has been assessed by Hattori et al; over 109 pregnant women, 3 (2.9%) of them have had a macroprolactinemia [6].

Several dosing methods serve to diagnose macroprolactinemia [7]. In our case, the diagnosis has been confirmed by Gel permeation chromatography, which remains the method of choice for its detection [8,9].

Macroprolactinemia is a common cause of hyperprolactinemia [10], but its research is not systematic [4]. According to two studies on 1225 [3] and 2089 [11] blood samples, macroprolactinemia frequencies have

been estimated by 26% and 22% respectively. In another study realized by Alfonso A. and al on 40 patients with hyperprolactinemia, 18 (45%) have had macroprolactinemia [12].

Macroprolactinemia is usually isolated [13], constituting the diagnosis of exclusion after a negative etiological investigation [2,10]. The etiological research requires clinical, biological and radiological investigations including MRI [14], which objectified the empty sella in our patient.

The particularity of our case is that, it is associated with a common cause of hyperprolactinemia which is the empty sella syndrome [15]. This association has not been described; however associations with a prolactinoma are possible. Mounier et al. have conducted a study on patients with macroprolactinemia, with whom we have discovered a micro-pituitary adenoma associated [16].

Macroprolactinemia reported during the Prolactinoma can reach up to 76% of the secreted prolactin. It is in fact composed of the complex monomer prolactin and circulating immunoglobulin G [17].

The discovery of a macroprolactinemia may have an important clinical and therapeutic impact [1,18], formerly neglected [10], avoiding the dopaminergic treatment led on our patient without interest for many years [4]. Several studies recommend systematic prolactin test [4,10,12,19].

The long-term assessment without treatment seems favorable [20].

## Conclusion

Our observation suggests that macroprolactinemia can be associated with conventional etiologies of moderate hyperprolactinemia as the empty sella syndrome. Its detection would prevent the use of dopaminergic therapy.

## References

1. Marteil AM, Sapin R, Jeandidier N (2000) La macroprolactine : implications biologiques et cliniques. *Immuno-analyse & Biologie Spécialisée* 15: 396-401.
2. Whittaker PG, Wilcox T, Lind T (1981) Maintained fertility in a patient with hyperprolactinemia due to big, big prolactin. *J Clin Endocrinol Metab* 53: 863-866.
3. Leslie H, Courtney CH, Bell PM, Hadden DR, McCance DR, et al. (2001) Laboratory and clinical experience in 55 patients with macroprolactinemia identified by a simple polyethylene glycol precipitation method. *J Clin Endocrinol Metab* 86: 2743-2746.
4. Richa V, Rahul G, Sarika A (2010) Macroprolactin; a frequent cause of misdiagnosed hyperprolactinemia in clinical practice. *J Reprod Infertil* 11: 161-167.
5. Andersen AN, Pedersen H, Djursing H, Andersen BN, Friesen HG (1982) Bioactivity of prolactin in a woman with an excess of large molecular size prolactin, persistent hyperprolactinemia and spontaneous conception. *Fertil Steril* 38: 625-628.
6. Hattori N (1996) The frequency of macroprolactinemia in pregnant women and the heterogeneity of its etiologies. *J Clin Endocrinol Metab* 81: 586-590.
7. Coussieu C (2000) The dosage of prolactine and immuno analyse and biological sample 15: 186-190.
8. Bonhoff A, Vuille JC, Gomez F, Gellersen B (1995) Identification of macroprolactin in a patient with asymptomatic hyperprolactinemia as a stable PRL-IgG complex. *Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association* 103(4):252-255.
9. Gilson G, Schmit P, Thix J, Hoffman JP, Humbel RL (2001) Prolactin results for samples containing macroprolactin are method and sample dependent. *Clinical chemistry* 47: 331-333.
10. Rudelli CC, Sapin R, Bonneville JF, Brue T (2007) Etiological diagnosis of hyperprolactinemia. *Annales d'Endocrinologie* 68: 98-105.
11. Gibney J, Smith TP, McKenna TJ (2005) The impact on clinical practice of routine screening for macroprolactin. *J Clin Endocrinol Metab* 90: 3927-3932.
12. Alfonso A, Rieniets KI, Vigersky RA (2006) Incidence and clinical significance of elevated macroprolactin levels in patients with hyperprolactinemia. *Endocr Pract* 12: 275-280.
13. Suliman AM, Smith TP, Gibney J, McKenna TJ (2003) Frequent misdiagnosis and mismanagement of hyperprolactinemic patients before the introduction of macroprolactin screening: application of a new strict laboratory definition of macroprolactinemia. *Clin Chem* 49 :1504-1509.
14. Donadio F, Barbieri A, Angioni R, Mantovani G, Peccoz BP, et al. (2007) Patients with macroprolactinaemia: clinical and radiological features. *Eur J Clin Invest* 2007 37: 552-557.
15. Wilson FM, Smith TP (2013) Determination of prolactin: The macroprolactin problem. *Best Pract Res Clin Endocrinol Metab* 27: 725-742.
16. Mounier C, Trouillas J, Claustrat B, Duthel R, Estour B (2003) Macroprolactinaemia associated with prolactin adenoma. *Hum Reprod* 18: 853-857.
17. Cavaco B, Leite V, Santos MA, Arranhado E, Sobrinho LG (1995) Some forms of big big prolactin behave as a complex of monomeric prolactin with an immunoglobulin G in patients with macroprolactinemia or prolactinoma. *J Clin Endocrinol Metab* 80: 2342-2346.
18. Olukoga AO (2002) Macroprolactinemia is clinically important. *J Clin Endocrinol Metab* 87: 4833-4834
19. Sapin JLS (2005) Macroprolactine. *Immunoanalyse and Biological Sample* 419: 265-342.
20. Vallette-Kasic S, Morange-Ramos I, Selim A, Gunz G, Morange S, et al. (2002) Macroprolactinemia revisited: a study on 106 patients. *J Clin Endocrinol Metab* 87: 581-588.